BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 11, 2025
Home » Newsletters » BioWorld

BioWorld

April 30, 2012

View Archived Issues

EUSA Swings an Ideal Exit with the $700M Acquisition by Jazz

The privately held UK specialty oncology firm EUSA Pharma Ltd. is to be acquired by Jazz Pharmaceuticals Inc. in a $700 million cash deal that is motivated by the early commercial success of EUSA's Erwinaze treatment for pediatric acute lymphoblastic leukemia (ALL), approved by the FDA in November 2011. Read More

Vivus Gains ED Approval; Obesity Still Center Stage

As expected, the FDA green-lighted Vivus Inc.'s erectile dysfunction drug Stendra (avanafil) on Friday, but analysts and investors remain focused on the looming July 17 PDUFA date for obesity drug Qnexa (phentermine/topiramate). Read More

Mitochondria's Bacterial Past Is Problem for Failing Hearts

Mitochondria, the energy-producing centers of cells, very likely got their start more than a billion years ago as bacteria that gradually went from a symbiotic relationship to a full-fledged part of the cells they colonized. Read More

Gilead's HIV Franchise Solid; HCV, Quad to Round out 2012

Gilead Sciences Inc. beat revenue estimates for the first quarter, but missed earnings-per-share consensus by 2 cents, as it reported solid sales for its antiviral franchise, including impressive uptake of recently launched triple-drug, single-tablet HIV drug Complera. Read More

Financings Roundup

• Supernus Pharmaceuticals Inc., of Rockville, Md., lowered the range for its proposed initial public offering (IPO). Read More

Other News To Note

• The International Myeloma Foundation, of North Hollywood, Calif., said a new drug application (NDA) has been submitted for pomalidomide, an immunomodulatory agent for multiple myeloma developed by Summit, N.J.-based Celgene Corp. The NDA is seeking use of the drug in patients who no longer respond to other therapies. Read More

Stock Movers

Read More

AAN Roundup

• Chelsea Therapeutics International Ltd., of Charlotte, N.C., said that in its randomized, double-blind, placebo-controlled trial (Study 301), Northera (droxidopa) showed statistical improvement compared to placebo for neogenic orthostatic hypotension. Read More

Pharma: Other News To Note

• Manhattan Pharmaceuticals Inc., of New York, changed its name to TG Therapeutics Inc. and implemented a one for 56.25 reverse stock split, which takes effect on April 30. Read More

Appointments and Advancements

• Veracyte Inc., of South San Francisco, named Richard Kloos senior medical director. Read More

Clinic Roundup

• Savara Pharmaceuticals, of Austin, Texas, reported top-line data from its Phase Ia study of AeroVanc, an inhaled antibiotic. AeroVanc (vancomycin hydrochloride inhalation powder) is a dry powder form of vancomycin in a capsule-based inhaler to treat respiratory methicillin-resistant Staphylococcus aureus infections in patients with cystic fibrosis (CF). Read More

Bench Press

Two Italian teams, one from the San Raffaele Telethon Institute and one from the University of Modena and Reggio Emilia, have shown that during gene therapy, vectors frequently integrate into the host genome in ways that leads to alternative splicing of the proteins they land in. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 11, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 10, 2025.
  • Novo Nordisk semaglutide pill

    CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

    BioWorld
    A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
  • RFK at Senate HELP meeting 5-14

    US lawmakers demand that Kennedy be held accountable

    BioWorld
    As the systematic dismantling of the U.S. vaccine schedule escalates, the demands to hold Health and Human Services Secretary Robert Kennedy accountable are...
  • Red dollar sign under microscope

    Medline plans record-setting $5.37B IPO

    BioWorld MedTech
    Almost a year since first filing its S-1 to return to public markets, Medline Inc. revealed the price range for the most awaited IPO of 2025. The massive medical...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing